Primarily used for patients suffering from nausea and vomiting, bloating, diarrhea, abdominal pain, electrolyte imbalances, acid-base imbalances, fatigue, malnutrition, and other conditions resulting in decreased mobility and quality of life.
Conditions
Interventions
Experimental Group:Under the guidance of physicians,both groups of subjects used the routine antiemetic regimen before hematopoietic stem cell transplantation conditioning chemotherapy, which involved
blank control group:Under the guidance of physicians, the two groups of subjects used t
Sponsors
First Affiliated Hospital of Zhejiang University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1: Diagnosed as hematological malignancy according to pathological and immunohistochemical staining criteria, with no contraindications for chemotherapy. 2: Subjects meet the indications for HSCT treatment: patients with malignant hematological diseases undergoing allo-HSCT with myeloablative conditioning (MAC) regimen; fully understand the study content, voluntarily participate and sign the informed consent form, and cooperate throughout the entire research process. 3: 18 years = age = 65 years. 4: Clear consciousness, with the ability to read and complete questionnaires independently. 5: The subject's Dranitsaris score is greater than 16 points.
Exclusion criteria
Exclusion criteria: 1: Participants with a history of intracranial hypertension, brain metastasis, electrolyte disorders, intestinal obstruction, tumor invasion into the intestine or other gastrointestinal abnormalities, or refractory nausea and vomiting caused by other comorbidities or other reasons. 2: Participants with concomitant mental disorders, cognitive impairments, or illiteracy who are unable to cooperate with the study or refuse to participate. 3: Participants with allergies to patches or who develop skin adverse reactions during the study, such as rashes, burning, itching, blisters, etc. 4: Participants with a history of skin-related diseases such as eczema, urticaria, psoriasis, fungal or bacterial infections, or herpes zoster.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in Nausea and Vomiting Symptoms;Objective Response Rate (Complete Response + Partial Response);Rescue antiemetic drug utilization rate;Differences in clinical symptoms in Traditional Chinese Medicine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life difference;Incidence rate of skin allergy adverse reactions.; | — |
Countries
China
Contacts
Public ContactDie Chen
First Affiliated Hospital of Zhejiang University Medical College
Outcome results
None listed